Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIAC once daily versus insulin detemir basal-bolus in type 1 diabetes
2008-005769-71Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2009
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in diabetes mellitus type 1 (T1D) comparing SIAC once daily plus mealtime insulin aspart with Insulin detemir plus mealtime insulin aspart (2 arms). Primary endpoint: Change from baseline in HbA1c after 26 weeks of treatment. Started Jun 2009; status: completed.
02
Drugs
insulin degludec + insulin aspartinsulin detemirinsulin aspart
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2008-005769-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005769-71.